Ownership and insider activity for Annovis Bio, Inc. (ANVS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Price
| Price | $1.04 |
| Market Cap | $44M |
| Exchange | NYSE |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $347472 | $35312 | $1858 | $8.1M | $45.7M | $28.4M | $5.8M | $10.6M | $19.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $735075 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | -$745.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $357963 | $50992 | $747512 | $8.1M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $357963 | $50992 | $1.1M | $8.1M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M |
| Accounts Payable | $71107 | $68425 | $1.2M | $341856 | $688074 | $4.0M | $1.3M | $2.3M | $2.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $490220 | $567943 | $2.0M | $578380 | $1.5M | $7.7M | $4.3M | $3.9M | $3.6M |
| Long-term Debt | 0 | 0 | $499807 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $7.3M | $7.6M | $9.7M | $578380 | $1.5M | $7.7M | $18.0M | $4.6M | $4.2M |
| Retained Earnings | -$7.1M | -$7.8M | -$8.8M | -$14.2M | -$28.7M | -$54.1M | -$110.3M | -$134.8M | -$163.7M |
| Total Equity | -$7.0M | -$7.6M | -$8.6M | $7.5M | $44.5M | $28.3M | -$7.8M | $9.3M | $16.9M |
| Total Debt | 0 | 0 | $499807 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$347472 | -$35312 | $497949 | -$8.1M | -$45.7M | -$28.4M | -$5.8M | -$10.6M | -$19.5M |
| Working Capital | -$132257 | -$516951 | -$1.3M | $7.5M | $44.5M | $28.3M | $5.9M | $10.0M | $17.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.44 |
Profitability
| Return on Equity | -685.96% |
| Return on Invested Capital | -400.40% |
| Return on Assets | -224.73% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATNM · BCAB · BTAI · CELU · ELUT · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of ANVS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks